Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy"

As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain

As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions

Administered to prevent thyroid blockage 130 mg orally 3 times a day,